Evidence-based peptide information for research and educational purposes only.
Navaro HealthNavaro Health
Energy & Endurance

L-Carnitine (Injectable)

← Back to Library
Label-verified Metabolic Mitochondrial
Educational reference only. Read the full disclaimer. The protocols below are not automatically an FDA-approved or clinically verified regimen unless explicitly marked as label-verified or human-trial protocol above.

Compound Profile

L-Carnitine (Injectable) is reviewed here for cellular energy, stamina, and recovery.

Research Summary

Evidence Strength Strong
Primary Evidence

Approved label, human clinical studies, regulatory sources

Research Focus

Cellular energy, Stamina, Recovery

Mechanism

Well characterized for approved products: Fatty Acid Transporters

Long-Term Data

Available for approved or studied uses.

Current Consensus

Research support is strongest when tied to approved products and studied use cases.

Route(s) Subcutaneous
Typical dose 200mg to 500mg
Dosing window Pre-Workout
Receptor / target Fatty Acid Transporters
Properties Not listed
Pre-mixed No

Protocols

Standard Protocol

TimeframeDoseNotes
Weeks 1+200mg to 500mg dailyAdminister pre-workout with a small carbohydrate source to spike insulin for cellular uptake.

Protocol example for research-context comparison; verify against the evidence status and listed medical sources.

Alternative Titration 1

TimeframeDoseNotes
Weeks 1-250 mg 1x Daily
Weeks 3-8100 mg 1x Daily
Weeks 9-12150 mg 1x Daily

Alternative research-context example; not an approved-label regimen unless marked above.

Protocol logic check

Protocol context: Energy protocols are usually about mitochondrial or metabolic signaling. The logic is timing around meals/training, avoiding late-day stimulation, and watching sleep, glucose, blood pressure, and overtraining signals. Entry context: target (Fatty Acid Transporters); route Subcutaneous; timing Pre-Workout. Label/trial anchors carry more weight than forum-style escalation.

Medical literature and study context

Medical-source summary: This section ties the page to medical literature, drug labels, trial registries, and regulatory sources. It is educational context only and should not be read as medical advice or a use recommendation.

Evidence positionApproved drug-label evidence exists for at least one product/indication, so label dosing, contraindications, and warnings are the strongest anchors.
Where studiedStudied in metabolism, mitochondrial function, substrate use, exercise physiology, glucose handling, or endurance models.
Source systems checkedDailyMed/NLM labels; FDA regulatory pages; PubMed/PMC literature; ClinicalTrials.gov records
Target and route contextTarget/receptor: Fatty Acid Transporters. Route(s): Subcutaneous. Dosing window on page: Pre-Workout.
Protocol anchorApproved-label anchor: Carnitor injection is IV. Metabolic disorders: 50 mg/kg as slow bolus or infusion with ongoing monitoring; ESRD on hemodialysis: 10-20 mg/kg dry body weight after each dialysis session.
Main evidence limitKey limitation: label evidence applies to labeled products, doses, routes, and populations; off-label or compounded versions may not share that evidence.

Source-linked findings

  • Levocarnitine injection has medical-label relevance for deficiency states; body-composition or performance claims rely on a separate, less direct evidence base.
  • Renal status, seizure history, gastrointestinal effects, fishy body odor, and anticoagulant interactions are practical safety checks.
  • No approved-label regimen was identified for this entry. Dosing examples should be treated as unverified protocol examples.

Protocol and study notes

  • Approved-label anchor: Carnitor injection is IV. Metabolic disorders: 50 mg/kg as slow bolus or infusion with ongoing monitoring; ESRD on hemodialysis: 10-20 mg/kg dry body weight after each dialysis session.
  • On-page protocol examples summarized for comparison: Standard Protocol: Weeks 1+, 200mg to 500mg daily; Alternative Titration 1: Weeks 1-2, 50 mg 1x Daily.
  • Key limitation: label evidence applies to labeled products, doses, routes, and populations; off-label or compounded versions may not share that evidence.
  • Monitor sleep, heart rate, blood pressure, glucose response, training load, appetite, and stimulant overlap.

Selected medical sources

Independent evidence

Approved label dosing: Carnitor injection is IV. Metabolic disorders: 50 mg/kg as slow bolus or infusion with ongoing monitoring; ESRD on hemodialysis: 10-20 mg/kg dry body weight after each dialysis session.
Independent safety notes: No approved-label regimen was identified for this entry. Dosing examples should be treated as unverified protocol examples.

Regulatory status: approved drug label available for levocarnitine injection

Storage

Store vials at controlled room temperature 25 C; avoid excessive heat; protect from freezing; discard unused portion because no preservative is present.

Contraindications & cautions

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.

  • Hypothyroidism (may interfere with thyroid hormone action): L-Carnitine acts as a functional thyroid hormone antagonist at the receptor level; it inhibits thyroid hormone entry into cell nuclei, reducing gene transactivation by T3 and T4; subjects with hypothyroidism should be aware that L-Carnitine supplementation may worsen hypothyroid symptoms or reduce the effectiveness of levothyroxine therapy.
  • Concurrent levothyroxine or thyroid hormone therapy: L-Carnitine's peripheral anti-thyroid action may reduce the effectiveness of thyroid replacement therapy; monitor thyroid function if co-administering.
  • End-stage renal disease (ESRD) without dialysis: L-Carnitine is renally excreted; accumulation to toxic levels is possible in severe renal failure; patients on hemodialysis may actually require carnitine supplementation due to dialytic losses, but administration should be clinically supervised.
  • Seizure disorder: rare reports of increased seizure frequency in subjects with pre-existing seizure disorders using L-Carnitine supplementation; mechanism not fully characterized; use with caution.
  • Known hypersensitivity to L-Carnitine or injectable formulation excipients.
  • Concurrent anticoagulant therapy (warfarin): case reports suggest L-Carnitine potentiates the anticoagulant effect of warfarin; INR monitoring is warranted if co-administering.
  • Trimethylaminuria (fish odor syndrome): subjects with impaired FMO3 enzyme activity cannot efficiently oxidize TMA to TMAO; even injectable carnitine metabolism may produce systemic TMA accumulation and severe body odor.

Possible side effects

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.

  • Fishy body odor (trimethylaminuria-like effect): the most characteristically reported adverse effect at higher injectable doses; occurs as L-Carnitine metabolism produces trimethylamine as a byproduct; some individuals are poor metabolizers of TMA to TMAO; the odor can be significant and socially notable; injectable routes reduce but do not eliminate this risk compared to oral.
  • Injection site pain and local reactions: injectable L-Carnitine solutions are often hyperosmolar; subcutaneous administration can cause burning, stinging, and localized irritation; IM injection is sometimes preferred for volume and tolerability reasons.
  • Nausea and gastrointestinal discomfort: more common with oral forms but reported with high-dose injectable use.
  • Diarrhea: at high doses; related to systemic carnitine load.
  • Headache: mild; occasional; mechanism not characterized.
  • Restlessness or mild insomnia: reported in sensitive individuals at higher doses; carnitine's role in mitochondrial activation may have a mild stimulatory quality in some subjects.
  • Hypothyroidism worsening: functional anti-thyroid effect in subjects with compromised thyroid function; thyroid-sensitive subjects should monitor thyroid panel.
  • Elevated TMAO (trimethylamine N-oxide): cardiovascular risk concern at chronic high doses; the injectable route mitigates but does not entirely eliminate TMAO production; relevance at standard research protocol doses is uncertain.
  • Muscle weakness in subjects with carnitine-related metabolic disorders: paradoxical; subjects with organic acidemias or other disorders of carnitine metabolism may experience unusual responses to supplementation.

Compatibility

The relationships below come from the compatibility note set and were Carnitor label states compatibility/stability in 0.9% sodium chloride or lactated Ringer's at specified concentrations for up to 24 hours at room temperature. independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

None listed.

Reported contraindicated combinations:

None listed.

Sources